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The ethnopharmacological approach toward the understanding and appraisal of traditional
and herbal medicines is characterized by the inclusions of the social as well as the
natural sciences. Anthropological ﬁeld-observations describing the local use of nature-
derived medicines are the basis for ethnopharmacological enquiries. The multidisciplinary
scientiﬁc validation of indigenous drugs is of relevance to modern societies at large
and helps to sustain local health care practices. Especially with respect to therapies
related to aging related, chronic and infectious diseases traditional medicines offer
promising alternatives to biomedicine. Bioassays applied in ethnopharmacology represent
the molecular characteristics and complexities of the disease or symptoms for which
an indigenous drug is used in “traditional” medicine to variable depth and extent. One-
dimensional in vitro approaches rarely cope with the complexity of human diseases
and ignore the concept of polypharmacological synergies. The recent focus on holistic
approaches and systems biology in medicinal plant research represents the trend toward
the description and the understanding of complex multi-parameter systems. Ethnophar-
macopoeias are non-static cultural constructs shaped by belief and knowledge systems.
Intensiﬁed globalization and economic liberalism currently accelerates the interchange
between local and global pharmacopoeias via international trade, television, the World
Wide Web and print media. The increased inﬁltration of newly generated biomedical
knowledge and introduction of “foreign” medicines into local pharmacopoeias leads
to syncretic developments and generates a feedback loop. While modern and post-
modern cultures and knowledge systems adapt and transform the global impact, they
become more relevant for ethnopharmacology. Moreover, what is traditional, alternative or
complementary medicine depends on the adopted historic-cultural perspective.
Keywords: knowledge transmission, globalization, medical pluralism, global economy, traditional medicines,
syncretism
INTRODUCTION TO ETHNOPHARMACOLOGY
Ethnopharmacology is a multidisciplinary ﬁeld of inquiry inves-
tigating the anthropological rationale and the pharmacological
basis of the medicinal use of plants, animals, fungi, micro-
organisms, and minerals by human cultures. An“interdisciplinary
approach is essential”. . . in “the attempts to present an equili-
brated appraisal of the therapeutic potential of an indigenous
drug” (Rivier and Bruhn, 1979). Richard Evans Schultes and Tony
Swain reasoned: “Peoples whom we have chosen to consider mem-
bers of less-advanced societies have consistently looked to the
Plant Kingdom”. . .. Should we as chemists, pharmacologists, and
botanists – with so many and varied means at our disposal – not
take a lesson from them?” (Rivier and Bruhn, 1979). While com-
mercial interests have always been a driving force behind the search
for new therapies, the global economy is accelerating the com-
modiﬁcation of indigenous and local knowledge (Posey, 2002).
But today, in a more globalized world, the concern has matured
that meanwhile “our goal should not be to freeze people in time.
Instead we must ﬁnd ways to ensure that in a pluralistic inter-
connected world all peoples may beneﬁt from modernity without
that engagement demanding the sacriﬁce of their ethnicity.”
(Davis, 2010).
Traditional medicine and medicinal plants are frequently used
in urban settings as alternatives in daily health care and self-
medication against minor and chronic ailments but especially
relied upon in less wealthy rural areas or times of economic crises.
Common to most systems of “traditional” or local medicine is
the adoption of a holistic perspective on human health. The
evaluation of descriptive ﬁeld-data, as well as the identiﬁca-
tion of anthropological aspects in traditional medicines, beneﬁt
from hypothesis-driven approaches. Well-deﬁned and testable
research questions in medical anthropology not only restrain
from arbitrary conclusions but also consolidate and foster the
bond between the social and the natural sciences. The focus
of ethnopharmacology centers on the bio-cultural investigation
and description of “traditional,” indigenous or local pharma-
copoeias and the experimental evaluation of materia medica
through biological test systems. The molecular characteristics and
complexities of the disease or symptoms for which a medici-
nal agent is used in “traditional” medicine are represented to
www.frontiersin.org July 2013 | Volume 4 | Article 92 | 1
“fphar-04-00092” — 2013/7/23 — 18:04 — page 2 — #2
Leonti and Casu Traditional medicines and globalization
variable depth and extent in the bioassays used to corroborate
the observed health claims. The ultimate goal of ethnopharma-
cology is contributing to evidence-based medicine, and to this
aim, conclusive negative results may be as important as positive
data.
CHALLENGES IN ETHNOPHARMACOLOGY
“Traditional” systems of medicine often recommend complex
herbal mixtures and multi-compound extracts. This polypharma-
cological approach is closer to the treatment of diseases related to
multifactorial causes such as chronic and degenerative ailments,
than biomedicine since here the concept of “one disease – one
target – one drug” does not hold (Ulrich-Merzenich et al., 2009;
Verpoorte et al., 2009). A mixture of moderately active metabo-
lites present in an extract are potentially able to interfere and
down regulate different proteins of the same signaling network
leading to synergistic pharmacological effects (Wagner andUlrich-
Merzenich, 2009). In this respect it was also pointed out that
reductionistic in vitro approaches are scarcely suited for the detec-
tion of synergistic properties or pro-drugs and how important it is
to follow a more holistic in vivo approach either via clinical trials
or animal experiments (Verpoorte et al., 2005). Since in vivo stud-
ies are not always feasible it has furthermore been outlined how
-omics approaches and systems biology are conceptually nearer to
the holistic perspective of ethnopharmacology (Verpoorte et al.,
2005; Zhang et al., 2010a). Metabonomics for instance tries to
measure as many metabolic factors as possible in order to asses
and better understand the alteration, perturbation and function-
ing of complex biological systems upon determined exogenous
stimuli such as medicinal plant extracts. Especially with respect to
Chinese medicine (TCM) -omic techniques are increasingly gain-
ing importance (for a review, see Buriani et al., 2012). Adopting a
systems approach for the analysis of quality and safety (Wang et al.,
2009) and rationalization of polypharmacological mechanisms or
network pharmacology (Hopkins, 2007) exerted by complex mix-
tures of compounds and extracts complies best with the holistic
standard of Chinese and Ayurvedic medicine (Joshi et al., 2010;
Zhang et al., 2010a).
The enormous amount and diversity of therapeutic uses of
traditional medicines described in literature, correlates all too
well with their activities assessed in one-dimensional bioassays.
Frequently exceedingly high – until the desired effect can be
observed – and therapeutically questionable concentrations of
extracts or natural products are applied to test systems. This is
also the point where the story usually ends as only few claims
observed in vitro can be repeated in vivo (Gertsch, 2009). The
matching of ethnomedical indications with biological test sys-
tems is not always straightforward and many plant species and
crude drugs are indicated and applied for different diseases and
symptoms at the same time within one culture and even to a
greater extend between different cultures (Spjut, 2005; Gyllen-
haal et al., 2012). Moreover, ethnopharmacopoeias are cultural
constructs and in constant exchange and transformation. Local
use of medicinal plants and associated cultural healing concepts
are able to co-exist with, and complement, the local commercial-
ization and use of pharmaceuticals. Such co-existence frequently
leads to syncretic developments as shown for rural indigenous
communities in Mexico and Peru (Giovannini et al., 2011; Moni-
gatti et al., 2012). Intensiﬁed globalization currently accelerates
the interchange between local and global pharmacopoeias not
only through international business interests but also via print
media, television and the World Wide Web generating a feedback
loop. The inﬁltration of global phytotherapeutical and biomed-
ical knowledge into local pharmacopoeias may lead to circular
argumentations in debates related to medical anthropology and
drug discovery (Leonti, 2011). The global commercialization of
herbal medicine and the emergence of what is called Complemen-
tary and Alternative Medicine as a social phenomenon during the
past decades is also due to the perception among Western soci-
eties, that the consumption of such products would be devoid of
health risks, especially in comparison to pharmaceuticals (Etkin,
2006, p. 207). However, such a perception is, for example, not
compliant with the philosophy and criteria of Chinese medicine,
which experimentally exploits the boundaries between toxic and
non-toxic applications of herbal formulas andmedicine in therapy
(Wang et al., 2012a). Also, deliberate or accidental adulterations or
misidentiﬁed herbal drugs constitute a continuous problem and
latent health risk (Ouarghidi et al., 2012; Walker and Applequist,
2012).
In this perspective review, we highlight the historical legacy
and development of ethnopharmacology, the relevance of human
diet and the importance of allelochemicals. The interface between
phytotherapy and drug discovery is evidenced with a discus-
sion on bioprospecting ancient texts, phylogenetic approaches
in ethnopharmacology, and evolutionary ecology. Through a
discourse touching on aspects of knowledge transmission, inte-
gration of medicinal systems, globalization, and medicinal plu-
ralism we tag economy and commercialism as a driving force in
ethnopharmacology.
THE GEARWHEEL OF ETHNOPHARMACOLOGY
In the introduction to the chapter of “Pharmacohistoria” to his
fundamental work “Handbuch der Pharmakognosie” (Handbook
of Pharmacognosy) Tschirch (1910, p. 446) quotes a colleague:
“. . .in its true sense no discovery is really independent, each [dis-
covery] is conditioned and most often also evocated by the actual
spirit of its time – in any case, however, primed by previousworks.”
In the following I shall give some historical sketches and examples
of how this quote may be interpreted.
Ergot, for example, the sclerotium of Claviceps purpurea (Fr.)
Tul. (Clavicipitaceae) was used as an abortifacient inCentral Euro-
pean folk medicine when Adam Lonicer (Lonicerus 1528–1586)
described its application for the ﬁrst time in 1582 (Ringrose,
1962). Women made use of repeated doses of three sclerotia
against pains in the uterus (Lonicerus, 1962, p. 525). Prior to
its acceptance as a birth-accelerating drug (thanks to the study by
Stearns, 1808) authorities tried to ban ergot’s use (Ginzburg, 1990,
p. 297). Indeed, ergot did not stand the test of time as a labor-
inducing agent since the risks for the unborn were too high and,
therefore, continued to be used only to stop the bleeding after par-
turition (Hofmann, 2002). The hemostatic principle of ergot was
ﬁnally isolated, elucidated and named ergometrine in 1935 (Stoll,
1935). In an attempt to optimize the pharmacological charac-
teristics of ergometrine Albert Hofmann (1906–2008) derivatized
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lysergic acid, the pharmacophore common to all ergot alkaloids,
with butanolamine (instead of propanolamine as in ergometrine)
obtaining methylergometrine, a compound with more favorable
qualities. Still today the 5-hydroxytryptamine (5-HT) antagonist
Methergin® is prescribed worldwide in midwifery for its reliable
uterus contracting and hemostatic action. Methysergide, another
ergometrine derivative interacting with 5-HT receptors was intro-
duced to the market as a prophylaxis of migraine headaches in
1961 (von Bruckhausen et al., 1993, p. 970).
After the success withmethylergometrine and in search of a cir-
culation and respiration activator,Hofmann synthesizedoneof the
most controversial compounds ever produced by humans: lyser-
gic acid diethylamide (LSD-25). LSD was introduced as a research
tool in psychiatry and sold under the name of Delysid by Sandoz
who propagated this strong entheogen as a psyche-decentralizing
agent in analytical psychotherapy (Hofmann, 2002, pp. 52–55).
During the late 1950s and the 1960s LSD was widely used in psy-
chotherapy alongside insulin shock therapy and with its psyche
opening quality served as a therapeutic alternative to the tranquil-
izers frequently used at that time (Sandison, 1959a,b). Despite
of the controversy accompanying the recreational use of LSD,
which is generally hold responsible for the decline of therapeu-
tic research with this psychedelic, it was recently pointed out how
the difﬁculties in establishing its efﬁcacy through controlled clini-
cal trials additionally contributed to LSD’s demise in experimental
psychotherapy (Oram, 2012).
The next example focuses on the same compound class but on
a completely different ethnological background. In the Florentine
Codex (a description of cultural practices in post-conquest Mex-
ico) Bernardino de Sahagún (1499–1590) refers to the indigenous
use of mind-altering mushrooms. The Florentine Codex is also
referred to as“TheHistoria General de las Cosas deNueva España”
(General History of the Things of New Spain; ca. 1545–1590) and
considered being the ﬁrst truly ethnographic study due to the
adopted methodological approach. In book 11 p. 130 Sahagún
reports on inebriating mushrooms: “It is called teonanacatl.” It
grows on the plains, in the grass. The head is small and round,
the stem ling and slender. . .it makes one besotted; it deranges
one, troubles one. It is a remedy for fever and gout. Only two
or three can be eaten. . .. He who eats many of them sees many
things, which make him afraid, or make him laugh. He ﬂees,
hangs himself, hurls himself from a cliff, cries out, takes fright.
One eats it in honey. . .of one who is haughty, presumptuous,
vain, of him it is said: “he mushrooms himself” (de Sahagún,
1961, Book 11, p. 130). Although Sahagún’s descriptions are quite
precise it was not until July 1938 when the anthropologists Bassett
Johnson (1915–1944) together with his wife and two colleagues
were invited to attend a ceremony in Huautla de Jimenez (Oax-
aca, Mexico) that the mushroom rite was rediscovered (Johnson,
1939; Wasson andWasson, 1957, p. 237). In the same year Richard
Evans Schultes (1915–2001) obtained fresh mushroom samples in
Huautla, which he identiﬁed as Panaeolus campanulatus L. var.
sphinctrinus (Fr.) Bresadola (Wasson and Wasson, 1957, p. 237).
The ﬁrst outsider to experience the effect of psilocybin containing
mushrooms was Gordon Wasson (1898–1986) who in 1953 par-
ticipated in a mushroom ceremony held by the curandera Maria
Sabina in Huautla. His subsequent report “Seeking the Magic
Mushrooms”published in Life Magazine brought this ancient and
local knowledge to a broad North-American audience and assured
that themushroom rite receivedworld-wide publicity. It was again
Albert Hofmann who in the late 1950s isolated and elucidated
the psychoactive principles of teonanacatl, the serotonin mimick-
ing psilocin and its pro-drug psilocybin, disenchanting the magic
mushrooms (Hofmann, 2002, pp. 118–126).
Both psilocybin containing mushrooms and LSD were soon
experimented with outside the scientiﬁc community and became
globally used recreational drugs inﬂuencing subcultures and
propelling countercultural movements. The triggering of over-
whelming psychedelic experiences led to the theory that the
administration of the classical hallucinogens would result in an
overall enhancement of brain activity in humans. This theory
was relatively well accepted until recently although no thorough
pharmaco-physiological studies of hallucinogen action have taken
place since the 1960s (Lee and Roth, 2012). Intriguingly, a new
study by Carhart-Harris et al. (2012) provide evidence that psilo-
cybin leads to a decrease of cerebral blood ﬂow and oxygen levels
suggesting that the subjective cognition is caused by a reduced
activity and decreased connectivity of the brain’s connector hubs
(Carhart-Harris et al., 2012). In an interesting survey subjective
case studies on cluster headache self-treatment with psilocybin
and LSD were gathered (Sewell et al., 2006). Cluster headache is
an extremely painful condition for which currently no medica-
tions terminating cluster periods or extending remission periods
are available. Although the survey’s limitation due to non-clinical
settings and an intrinsic selection bias, the results are intrigu-
ing, also because the apparent effectiveness of sub-hallucinogenic
doses. A prophylactic effect of psilocybin perceived as complete
cessation of attacks was reported by 52% of psilocybin users,
while a further 41% reported a decreasing intensity and frequency
of cluster headache attacks. Respondents also reported extension
of remission period upon LSD and psilocybin consumption (see
Sewell et al., 2006). New insights into the pharmaco-physiological
interactions of hallucinogens and surveys conducted with indi-
vidual users might help for a more directed and concerted use of
psychedelic compounds in psychotherapy and pain therapy.
In the biogeographic study “On the trail of the ancient opium
poppy” Merlin (1984) traces the cultural expansion of one of the
most important and potent drug plants. Today opium alkaloids
are a worldwide therapeutic commodity, while their molec-
ular scaffolds inspired scores of pharmaceutical chemists and
pharmacologists alike. One of the major concerns of medical
opioid administration is the fast development of tolerance and
withdrawal symptoms as well as minor complications such as con-
stipation, emesis, and drowsiness (Darvishzadeh-Mahani et al.,
2012). Recent experimental research on the therapeutic value of
opioids (remifentanil) shows that single but highly dosed opi-
oid administration reverses hyperalgesia in rats (Drdla-Schutting
et al., 2012). This ﬁnding suggests that in case of hyperalge-
sia, instead of chronic low dose opioid administration, brief
but highly dosed opioids might erase chronic pain persistently
(Drdla-Schutting et al., 2012).
Also ginger (Zingiber ofﬁcinale Roscoe, Zingiberaceae) besides
its status as a spice and food item, has become a global medici-
nal commodity used against rheumatism, headache and above all
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against digestive and respiratory problems showing potent anti-
inﬂammatory properties in vitro and in vivo (Chevallier, 2000;
Williamson, 2002; van Breemen et al., 2011). While paradol, was
found to inhibit COX-1 (Nurtjahja-Tjendraputra et al., 2003) 10-
gingerol, 8-shogaol and 10-shogaol were shown to inhibit COX-2
(van Breemen et al., 2011) but shogaols and gingerols further-
more concurrently inhibit IL-1β and prostanoid secretion leading
to strong upstream anti-inﬂammatory effects (Nievergelt et al.,
2011). Murine in vivo data suggest that ginger extract adminis-
tration is able to prevent morphine tolerance as well as naloxone-
induced withdrawal signs (Darvishzadeh-Mahani et al., 2012). As
an underlying mechanism L-type channel blocking properties by
ginger constituents leading to an attenuation of calcium chan-
nel over expression induced by morphine has been suggested
(Darvishzadeh-Mahani et al., 2012). The therapeutic beneﬁt of
ginger in this context might include its anti-inﬂammatory poten-
tial as it was shown that morphine triggers neuroinﬂammation
in the CNS mediated via binding to the Toll-like receptor 4
(Wang et al., 2012b). Well-conducted clinical trials on the ther-
apeutic efﬁcacy and effectiveness of ginger preparations in painful
inﬂammatory conditions are, however, still lacking (Terry et al.,
2011).
Bacopa monnieri (L.) Pennell (Scrophulariaceae) is an impor-
tant Ayurvedic medicinal plant used for a variety of health
problems but above all to treat mental problems (Williamson,
2002; Russo and Borrelli, 2005). Since its Hindu name “Brahmi”
is also valid for the Apiaceae species Centella asiatica L. (Sanskrit:
Mandukaparni) the ﬁrst written accounts are difﬁcult to assign
to either of the two species (see Hoernle, 2011, p. 301). Phyto-
chemical analyses with B. monnieri started as early as 1931 and
two saponins, bacoside A and B, are considered to be respon-
sible for the neuropharmacological effects, while clinical trials
with standardized extracts have shown promising results (Russo
and Borrelli, 2005). Recent experimental data obtained with rats
suggests that B. monnieri leaf extract up-regulates expression of
tryptophan hydroxylase and serotonin transporters (Charles et al.,
2011). A randomized controlled trial over a long-term period with
a standardized B. monnieri extract is currently assessing the cogni-
tive performance of subjects and tries to ﬁnd correlations with and
between inﬂammation, oxidative stress and cardiovascular health
(Stough et al., 2012).
Semisynthetic derivatives of artemisinin, obtained from the
ancient Chinese medicinal herb “qing hao” (Artemisia annua L.,
Asteraceae) are used in combination therapies and are a mainstay
in the treatment of malaria (Kumar and Clark, 2001, pp. 80–
81; Hsu, 2006). Artemisinin is a highly bioactive sesquiterpene
lactone containing a 1,2,4-trioxane pharmacophore and its possi-
ble molecular mode of action has caused some debate (O’Neill
et al., 2010). Besides artemisinin’s anti-plasmodial activity also
its anti-tumor activity has come into focus (Woerdenbag et al.,
1993; Efferth,2007). The same rationale proposed for artemisinin’s
anti-plasmodial activity may explain the sensitivity of cancer cells
toward artemisinin (Mercer et al., 2011). Recent evidence suggests
that hemoglobin degradation products such as heme are activating
artemisinin leading to carbon-centered radicals exerting oxida-
tive stress in the parasite (Klonis et al., 2011; Mercer et al., 2011).
Artemisinin derived anti-malarial drugs are, however, not easily
accessible or affordable to a large portion of the malaria struck
population (Kokwaro, 2009; Wright et al., 2010). Therefore, A.
annua has been introduced to rural areas afﬂicted by malaria epi-
demics around the globe for self-medication purposes. Locally
grown and carefully prepared and applied herbal tea of A. annua
could present a reasonable and affordable alternative (Wright et al.,
2010; van der Kooy and Verpoorte, 2011). When adopting the
preparation methods described in ancient Chinese medicinal texts
it was shown that only a fraction of pounded juice is needed with
respect to the quantity of aqueous infusion in order to provide the
required amount of artemisinin (Wright et al., 2010). However,
also by applying the correct infusion method artemisinin extrac-
tion efﬁciencies up to 90% can be reached (van der Kooy and
Verpoorte, 2011).
Intriguingly, a survey about the anti-malarial use of A. annua
in Kenya andUganda revealed that in themeantime a considerable
part of the respondents use the herb also against HIV/AIDS (Will-
cox et al., 2011). Encouraged by this report Lubbe et al. (2012)
showed that A. annua as well as A. afra Jacq ex Willd., which
does, however, not contain artemisinin, exhibit potent anti-HIV
activity in vitro. Although the identiﬁcation of the responsible
compound(s) as well as in vivo studies are still due, Lubbe et al.
(2012) have pointed out how people adapt their pharmacopoeia to
the emergence of new diseases and epidemics. The use of “magic
mushrooms” and LSD to treat cluster headaches and the use of
A. annua in rural areas of Africa to combat HIV infection high-
lights that serendipity and the perception of collateral properties
in the search of newmedical therapies still plays an important role.
Especially during the appearance of new diseases, lack of ﬁnan-
cial resources and in cases where no effective treatment methods
exist (Sewell et al., 2006; Willcox et al., 2011) ethnopharmacology
may lead us to effective therapies. These cases also highlight that
ethnopharmacological research is not dependent on “traditional”
knowledge systems in the narrower sense but that there exist feed-
back loops wherein modern and post-modern knowledge systems
are becoming more relevant.
DIET AND ETHNOPHARMACOLOGY
Etkin andRoss (1991)were referring to the“extra-nutritive”aspect
of food phytochemistry and associated pharmacology when they
asked whether we should “set a place for diet in ethnopharma-
cology”. The evolutionary perspective of health and nutrition
comprises the co-evolution of the food-medicine continuum of
wild gathered and cultivated vegetables (Etkin, 2006; Lindeberg,
2010; Leonti, 2012). Especially wild gathered food plants are
often reported in local and popular traditions to have pharmaco-
logic activities and are frequently associated with beneﬁcial effects
on the gastrointestinal tract, the cardiovascular system and with
diuretic properties (e.g., Pardo-de-Santayana et al., 2005; Rivera
et al., 2005; Guarrera and Savo, 2013). But although domesti-
cation of staple crops has led to a reduction of allelochemicals
(Johns, 1990, pp. 102–159; Etkin and Ross, 1991), regularly con-
sumed food products may provide relevant concentrations of
pharmacologically active plant metabolites.
The focus thus falls on pharmacological properties of alle-
lochemicals present in food, i.e., the bioactivity of secondary
metabolites that evolved upon ecological constraints such as
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herbivory and not on our physiologic requirement for vita-
mins, pigments (carotenoids, lycopene) and fatty acids, which
is considered in nutrition sciences (cf. Lindeberg, 2010; Carrera-
Bastos et al., 2011). Also, antioxidant in vitro activities exerted by
polyphenol-rich extracts and polyphenolic compounds such as
ﬂavonoids are hardly translatable into in vivo conditions and thus
fall not in the narrower focus of ethnopharmacology. Following
evolutionary concepts it was pointed out that ﬂavonoids did not
evolve for the purpose of scavenging free radicals (Zhang et al.,
2010b).
The human dependence on salt in regions far from the seashore
is occasionally satisﬁed by the production of vegetable salts from
plant ashes. The salt obtained from the Witoto “woman-plant”
(Bactris humilis (Wallace) Buret, Arecaceae) showed a remarkably
high content of zinc and sodium with respect to salts obtained
from other plant ashes. Zinc is a microelement required by preg-
nant and lactating women, while sodium is important for the
retention and formation of amniotic liquid and might explain
why the Witoto refer to B. humilis as “woman-plant” (Echeverri
and Román-Jitdutjaaño, 2011).
A more regular example is the use of highly toxic Aconitum as
root vegetable in the region of Shaanxi (China; Kang et al., 2012).
Before being consumed, tubers of cultivatedAconitum carmichaelii
Debeaux are boiled for up to 10 h, leading to degradation prod-
ucts of the diterpene alkaloids, which are far less toxic (Kang et al.,
2012). The input for this dish, which is only consumed during
the cold season and considered a “functional food” is in any case
remarkable andwarrants an ethnopharmacological analysis. Apart
from the nutritional factors the ancient Romans highly appreci-
ated the medicinal properties of cabbage, which they used for
interior and external ailments (Matthioli et al., 1967–1970, book
2, p. 498). The claim that the juice of kale leaves has gastro-
protective effects, preventing the formation of ulcers has been
experimentally assessed (Carvalho et al., 2011; Lemos et al., 2011).
Aqueous and hydroalcoholic Brassica oleracea L. (Brassicaceae)
extracts (50–100 mg/kg) were found to be as effective as the posi-
tive controls in preventing experimentally induced gastric lesions
in murines.
Insufﬁciently validated health claims and aggressive marketing
strategies may, however, lead to negative socio-economic impacts
on the local level. It was for instance not possible to date to scientif-
ically conﬁrm the claimed health beneﬁts of açai (Euterpe oleracea
Mart., Arecaceae) that range from rapid weight loss, prevention
of cardiovascular diseases and aging in general (Heinrich et al.,
2011). After an initial boost of worldwide açai commercialization
triggered by local and globalmedia coverage (Heinrich et al., 2011)
the global sales of açai berries are expected to drop leaving trade
volume to other, scientiﬁcally better corroborated nutraceuticals.
In such a scenario local Brazilian farmers would be left empty
handed. Another fruit enjoying growing popularity on the global
health food market is the Goji berry (Lycium spp., Solanaceae;
Potterat, 2010). While Goji berry products are considered a tonic
and the juice a longevity drink, no such claims have hitherto been
corroborated by scientiﬁc data not to mention by clinical studies
(Potterat, 2010).
A closer cooperation of ethnopharmacologists with the agri-
culture sectors in areas such as food production, nutrition and
health could counteract such scientiﬁcally deregulated develop-
ments (Heywood, 2011). It remains to be seen, however, what the
priorities of the agriculture sector and the nutraceuticals industry
are; easy money or controlled and rational health claims?
Turmeric (Curcuma longa L., Zingiberaceae) is an important
ingredient in Indian andChinese cuisine andmedicine. India is the
biggest producer and consumer of turmeric, while the US imports
of turmeric stem to the largest extent from India. With respect to
crude botanical materials, where the product price increases dra-
matically along the value chain (producer to consumer) without
receiving additional value (ﬁnal product is unprocessed) products
including turmeric generally receive added value through differ-
ent processing methods (Booker et al., 2012). In the case of mere
encapsulated turmeric, which confers a medicinal appearance to
the end product a 10-fold price increment has been observed
(Booker et al., 2012). The active metabolite, curcumin, is actu-
ally a mixture of the three preponderant diferuloylmethanes also
used as a colouring agent in food industry and labeled “E 100.” A
large body of in vitro and in vivo evidence has been accumulated
conﬁrming curcumin’s anti-inﬂammatory properties (Goel et al.,
2008). Clinical studies evidenced curcumin’s therapeutic relevance
with rheumatoid arthritis, psoriasis, inﬂammatory bowel disease,
inﬂammatory eye disease, and kidney transplantation (White and
Judkins, 2011). In practice, however, curcumin administration
suffers from themolecule’s hydrophobic nature, which determines
its poor absorption, rapid metabolism, and limited tissue distri-
bution. Also therefore, curcumin is well tolerated and regarded as
safe, while doses as high as 12.000 mg per day have resulted in no
signiﬁcant adverse effects (Lao et al., 2006; Anand et al., 2007; Hsu
and Cheng, 2007). Bioavailability of curcumin is, however, not
so much an issue with the gastrointestinal tissues, mucose mem-
branes in general and skin lesions, which can be exposed directly
to biologically active concentrations (Hsu and Cheng, 2007). But
curcumin has been shown to act as an iron chelator able to inter-
fere with iron metabolism (Jiao et al., 2009). In patients with
marginal iron stores curcumin supplementation may therefore
lead to or aggravate anemia (Jiao et al., 2009). A possible solution
with the aim at overcoming curcumin’s poor bioavailability and
enhancing its aqueous dispersion is nanoparticle-encapsulation
(Bisht et al., 2007). A mixture of curcumin with piperine, an
alkaloid obtained from pepper (Piper nigrum L. and P. longum
L., Piperaceae) able to enhance curcumin’s bioavailability via the
inhibition of hepatic and intestinal glucuronidation (Shoba et al.,
1998) has already been released to the market. Other brands con-
tain mixtures of curcumin and broccoli (Brassica oleracea var.
italica Plenck, Brassicaceae) seed extract with up to 6%of detoxify-
ing sulfhoraphane glucosinolates and are currently sold for 39.95
USD (end user price) a bottle containing 30 servings (see also:
http://www.youtube.com/watch?v=ZuvhiiD1qAk).
By nature of its assignment a completely different perspective
regarding curcumin’s use as a food dye has been adopted by the
European Food SafetyAuthority (EFSA; EFSA,2010). Even though
several previous safety evaluations by a joint FAO/WHO expert
committee on food additives from 1974 to 2004 have established
that curcumin was acceptable for use in food, EFSA re-evaluated
the use of curcumin eliminating concerns over genotoxicity and
concluding that consumption up to an average daily intake of
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3 mg/kg bodyweight is safe (EFSA, 2010). This example highlights
how different aims and perspectives generate disparate hypothesis,
although EFSA’s concerns were primarily the chronic exposure to
curcumin.
Recent commercial endeavors by the nutraceutical industry
reveal a trend toward sophisticated formulations adopting the con-
cept of polypharmacology or “network pharmacology.” Instead of
approaching pharmacology with the concept of “one lock” (tar-
get) and “one key” (drug) Hopkins (2007) argued that one should
consider that there are drug target networks and not just sin-
gle disconnected drug targets. In herbal combination formulae
practiced, for example in Ayurvedic and in Chinese medicine the
pharmacokinetics and – dynamics of a single or a couple of com-
pounds may be inﬂuenced by the rest of the metabolites present
in the extract (Aggarwal et al., 2011; He et al., 2012, see Chal-
lenges in Ethnopharmacology). Medicinal plants have, however,
not been “designed” to cure human diseases or alleviating their
symptoms and undesired antagonistic effects are equally realis-
tic. Re-engineer botanical drugs by designing extracts driven by
therapy success could be a way forward toward “more intelligent
mixtures” (Gertsch, 2011). The strategy of polypharmacology is as
old as medicine itself and the food supplement industry provides
several examples where phytochemicals of different vegetables,
fruits or spices are blended to provide synergistic servings appear-
ing as “molecular novel cuisine.” One should, however, keep in
mind, that a variegated and balanced diet not only tastes better
than pills and capsules, but is also healthier.
DIACHRONIC STUDIES AND BIOPROSPECTING
ANCIENT TEXTS
Since culture is not static but in a constant ﬂux the impor-
tance of materia medica is exposed to different socio-economic
factors and may change over time. These factors comprise cul-
tural interaction (e.g., migration), change in diseases prevalence,
lack or prove of efﬁcacy and effectiveness, introduction of ther-
apeutic alternatives (e.g., biomedicine), change in availability of
new species and products and ecology (e.g., agricultural prac-
tices). Changes in medicinal plant use can be perceived as
“continuity” (maintenance), “disjunction” (same species but new
context or conceptual background), “discontinuity” (abandon-
ment) and synchronism (substitution and adoption; see Bye et al.,
1995). Odonne et al. (2011) found only one out of ﬁve previously
described plant species used by the Wayãpi against leishmaniasis
still in use, while previously not reported species are now relied
upon. Generally ﬁeld studies onmedical ethnobotany show“snap-
shots,” i.e., the status quo of medicinal plant use for a certain
community and point in time. Writing has enabled physicians,
explorers, historians, and merchants to document, conserve and
pass on gathered information and knowledge on medical plant
use in codices, manuscripts and books. Thanks to these writ-
ten sources plant uses can be traced diachronically through ages
and over centuries up to the present usage (e.g., Leonti et al.,
2010; Luczaj, 2010; Sõukand and Kalle, 2011; Obón et al., 2012;
Pieroni et al., 2013) and even causal inﬂuences of herbal texts on
modern local plant use can be observed (Leonti et al., 2010). Con-
sequently, ﬁltering down to the popular level, scientiﬁc literature
inﬂuences local plant use and thereby shapes the results of current
ethnobotanical ﬁeld-studies. Quantitative diachronic evaluations
of plant use additionally provide historic depth and information
on the therapeutic rationales but of course would not be possible
without “snapshots.” In the words of Steve Jobs (1955–2011) this
approach reads “You can’t connect the dots looking forward; you
can only connect them looking backwards” (Jobs, 2005).
Today, information regarding the use of medicinal and food
plants is readily accessible via the WWW. While until recently
global migration and urban environments were in the focus
of changing and persisting plant use, the WWW increasingly
strengthens such dynamics and renders them even more complex
(Casselman and Heinrich, 2011). How the video-sharing platform
YouTubeTM is disseminating and inﬂuencing global use pat-
terns regarding the hallucinogenic application of Salvia divinorum
Epling and Játiva (Lamiaceae) through user generated contents has
been highlighted recently (Casselman and Heinrich, 2011).
In more economically developed countries and regions herbal
medicine and phytotherapy is used as a therapeutic alternative to
biomedicine for the treatment of mild and chronic health prob-
lems. Complementary and alternative therapies are also used to
sustain conventional medicine and to treat their side effects such
as the collateral symptoms frequently occurring during cancer
therapy (Kronenberg et al., 2005). Moreover, today, a part of the
world’s population has the choice of using herbal medicine (and
also nutraceuticals) also as a fashionable life-style treatment. In
many parts of the world conditions and opportunities for exper-
imenting with herbal medicines in case of sever and acute health
problems are not given anymore. Therefore, one question arising
here relates to the differences in the application and function of
for instance TCM or Ayurvedic medicine in rural and deprived
societies with respect to a more prospering population.
During the pre-biomedical era, the use of herbal medicine and
materia medica, together with primordial surgery and healing cer-
emonies were the only form of medical treatment. Historical texts
documenting the ancient use of materia medica contain informa-
tion, which is not present anymore in local knowledge of com-
munities pertaining to industrialized nations. Therefore, ancient
herbals may reveal interesting information for bioprospecting
attempts. Buenz et al. (2004) provide some practical and theo-
retical considerations for approaching historic texts on materia
medica as a source for drug discovery. Plant and drug identiﬁca-
tion in ancient texts can be challenging especially when a wide
range of names is used for the same product and when no images
are available (Lev, 2007). Another crucial point relates to the cor-
rect interpretation of the description of diseases, ailments, and
the respective etiologies. When iconographical studies together
with textual interpretations are possible (e.g., the case for most
Renaissance herbals) the identiﬁcation of most materia medica,
is relatively straightforward, especially to the genus level. More
complicated may be the correct interpretation of descriptions of
amorphous products such as plant exudates (Lardos et al., 2011).
Malaria, for instance, was widespread in Europe and only erad-
icated toward the mid-twentieth century. The European Renais-
sance herbals make clear distinctions between remedies against
malaria tertiana (Plasmodium vivax), and malaria quartana (Plas-
modium malariae; Adams et al., 2011a). However, published data
regarding their anti-plasmodial in vitro activity exist only for the
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minority of the taxa indicated against malaria in eight differ-
ent German Renaissance herbals (Zimmermann et al., 2012). A
comparative screening involving extracts obtained from species
indicated against malaria and a control group of European medic-
inal species with indications other than malaria showed nine
out of the ten most active extracts deriving from species with a
documented anti-malarial use (Zimmermann et al., 2012). From
frog’s spoon (Alisma plantago-aquatica L., Alismataceae), which is
described in different sixteenth and seventeenth century herbals
against“three”and“four day”fevers, protostane triterpenoids with
moderate anti-plasmodial in vitro activity were isolated (Adams
et al., 2011b).
EVOLUTIONARY ASPECTS OF PHARMACOPOEIAS AND
BIOPROSPECTING WITH PHYLOGENETIC APPROACHES
While drug discovery from natural products focuses on pure
bioactive and bio-available, “drug-able” chemical entities, herbal
medicine and phytotherapy research pursues the characteriza-
tion of more complex pharmacological interactions exerted by an
extract containing diverse chemical entities. The historical legacy
testiﬁes that ethnopharmacologyhas contributed tobothdomains,
drug discovery and the development of herbal medicines (Elvin-
Lewis,2001; Fabricant andFarnsworth,2001). Bothdomains focus
on secondary metabolites, adaptive traits that evolved in response
to ecological pressures. The fact that closely related taxa showmore
similar patterns of secondary metabolites than phylogenetically
distant taxa, can be exploited for chemotaxonomical approaches
in drug discovery.
A recent census regarding the taxonomic source of FDA
approved and clinical-trial natural product drugs has provided
evidence for a non-random distribution with clustered and dis-
junct taxonomic afﬁliations (Zhu et al., 2011). From a total of 740
existing Viridiplantae families (comprising ca. 450 Angiosperm
families) only 59 families of the Angiospermae, four of the Gym-
nospermae, three of the mosses and one of the algae family
provide all FDA approved and clinical-trial natural product drugs
derived from plants (Zhu et al., 2011). Many of the Angio- and
Gymnosperm species censed by Zhu et al. (2011; S5–S7) are also
elements of local ethnopharmacopoeias and used in global herbal
medicine or are used as spices and staple food and derive from
an intimate human-plant relationship and have a history of an
ethnopharmacological use. The “traditional” indications of the
herbal medicines are, however, far more diverse and not always
congruent with the biomedical applications of the puriﬁed and
FDA approved compounds (Leonti et al., 2013). Similarly to FDA
approved drugs, also the compositions of ethnopharmacopoeias
show disproportionate selections of the available ﬂora. Several
statistical studies have pointed out that certain plant families
(e.g., Asteraceae, Lamiaceae) are generally over proportionally
relied upon for a selection within indigenous and local phar-
macopoeias, while others (e.g., Poaceae and Orchidaceae) are
normally a neglected source of medicine (e.g., Moerman et al.,
1999; Saslis-Lagoudakis et al., 2011; Thomas et al., 2011; Weckerle
et al., 2011; Weidenhammer et al., 2011; Turi and Murch, 2013).
Most of these studies focus on ecological and universal aspects
of herbal medicine and the different factors inﬂuencing plant
selection,or advocate such statistical approaches as bioprospecting
tools. A more sophisticated approach toward bioprospecting with
comparisons of medicinal ﬂoras uses reconstructed phylogenies
of ethnopharmacopoeias (Saslis-Lagoudakis et al., 2012). Exactly
which practical instructions for bioprospecting purposes might be
obtained from cross-cultural comparisons, or the analysis of dis-
proportionate inclusion of plant taxa in pharmacopoeias, without
considering the inﬂuence of other parameters, have both been put
up for discussion (Gertsch, 2012).
Herbal medicines usually work with their entire bio-available
chemical proﬁle in synergistic and antagonistic relationships,
which exacerbates bioprospecting attempts. Moreover, factors
inﬂuencing medicinal plant selection by human communities are
manifold ranging fromecology, cultural history, human cognition,
and medical anthropology. Recently the ﬁrst author characterized
the prototypical medicinal plant as “an abundant Euasterid weedy
species, possibly utilizable as food, routinely attracting pollinators,
rich in pharmacologically active and bio-available metabolites,
endowed with pronounced organoleptic properties and ideally,
with a bit of fantasy, the signature of the organoleptic virtues
could be matched with the plant’s medicinal indication, which
thereby would facilitate its transmission and through the belief
in its semiotic appearance at the same time enhance the mean-
ing response of its medical application” (Leonti, 2011). But one
of the crucial points with respect to drug discovery is that most
medicinal species are used for a wide range of therapeutic appli-
cations, which renders the formulation of tangible instructions
for bioprospecting attempts difﬁcult. It has also been shown that
when indigenous medicines are evaluated across a range of bioas-
says, ethnomedical indications rarely correspond with meaningful
screening results (Gyllenhaal et al., 2012). A particularly interest-
ing fact is, however, that plant species used as medicine by human
societies achieve higher number of hits with respect to random
collections when screened in cell based and mechanistic bioassays
(Spjut and Perdue, 1976; Gyllenhaal et al., 2012).
This may be due to the overrepresentation of weeds and
widespread taxa in local and ofﬁcial pharmacopoeias (Stepp and
Moerman, 2001; Stepp, 2004); it has been proposed that taxa with
wide biogeographical distributions have encoded a broader range
of ecological responses in their genes with respect to more locally
occurring taxa (Leonti et al., 2013). These responses include the
synthesis of allelochemicals with broad-spectrum biological inter-
actions, comprising the targeting of proteins of mammals and
primates.
MEANING RESPONSE, EFFICACY, AND EFFECTIVENESS
With respect to biomedicine, traditional systems of medicine base
diagnostics, perception of illness and healing traditions on elabo-
rate, and from a Western scientiﬁc point of view, challenging (if
not unacceptable) philosophy (e.g., Jiang et al., 2012; Mukherjee
et al., 2012; see Foster and Anderson, 1978). Often these philoso-
phies are grounded on physiologic equilibrium models, which
are also expressed through curing rites and psychosocial sup-
port (Foster and Anderson, 1978). Such philosophies and holistic
approaches comfort the end-user and thereby impart a beneﬁcial
and self-afﬁrming “placebo effect” also called “meaning response”
(cf. Moerman and Jonas, 2002). Higher expectation on treatment
outcome by patients with chronic pain had a signiﬁcant impact on
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the effectiveness of acupuncture therapy (Linde et al., 2007). It has
been suggested that psychological factors such as expectation and
behavioral conditioning are able to induce neurobiological mech-
anisms that interact with pharmacological pathways (Bingel et al.,
2011; Rief et al., 2011). Although the pharmacological assessment
and evaluation of the meaning response goes beyond capabili-
ties of standard pharmacology laboratories, the relevance of the
placebo and the nocebo effect may not be recognized enough: the
therapeutic context, in which an optimal drug efﬁciency may be
achieved should be included in the treatment recommendations
(Rief et al., 2011). Even though 25 years ago Etkin (1988) already
pointed out how drug efﬁcacy depends on the speciﬁc socio-
cultural context, this insight has not been incorporatedwidely into
clinical studies to the extent itmight deserve (Witt,2013). Last et al.
(2011) deﬁned “efﬁcacy” as treatment outcomes obtained under
ideal and standardized conditions (e.g., clinical study setting) as
opposed to “effectiveness,”which is used to describe the therapeu-
tic success in routine and non-experimental circumstances (see
also Witt, 2013). As globalization changes socio-cultural contexts
one can expect that the current development will have an impact
on the meaning response of a speciﬁc therapy. For example in
Western societies“more”is regarded as“better”above all in relation
to monetary affairs. One plausible hypothesis would therefore be
that more sophisticated and costly a (herbal) preparations would
achieve more pronounced placebo effects, and hence effectiveness,
also on the global scale.
TRADITIONAL MEDICINES: GLOBALIZATION, KNOWLEDGE
TRANSMISSION, INTEGRATION, AND MEDICAL
PLURALISM
For the largest part of human history information and knowledge
has been transmitted orally and by observation and direct copy-
ing. With the advent of writing systems a more precise copying
and knowledge transmissionwas possible and thanks to scripts the
transmission of knowledge related to material medica over wide
ranges of space and time was possible. Oral and written knowl-
edge transmission is in constant exchange and written knowledge
may result in changes to traditions, which are then passed on
orally – and vice versa – and from that point of view a dichotomiza-
tion makes no sense (Totelin, 2009). However, there exists a clear
quantitative difference in knowledge transmission emanated by
texts used as guides and references over a long period of time,
over broad geographical extensions and diverse cultural back-
grounds. Generally, scripts allow a more conservative knowledge
transmission and may lead to a homogenization of knowledge
(Leonti, 2011).
That goods and associated knowledge from Indian andChinese
materia medica were exchanged along the Silk Road reaching and
inﬂuencing early Mediterranean medical traditions can be traced
in scripts dealing with materia medica at least from the ﬁfth to the
fourth century BC onward (Touwaide and Appetiti, 2013). On the
other hand received theHindu systemof medicine at the same time
apparently little external inﬂuences. A collection of 51 birch-bark
leaves known as the Bower Manuscript is regarded as the old-
est still existing script dealing with Hindu medicine (Winternitz,
1902). It was discovered in Kucha (Chinese Turkestan) situated on
the Silk Road in 1889, translated by the German-British orientalist
Rudolf Hoernle (1841–1918) and dated to the ﬁfth century AD.
Not even opium, which at that time was one of the most impor-
tant drugs in the Mediterranean and the Near East, is mentioned
in the Bower Manuscript (Tschirch, 1910, p. 508; Hoernle, 2011).
Although earlier, and now lost, medicinal scripts dealing with
ancient Hindu medicine existed, such medical knowledge within
India has mainly been passed on by practitioners and through the
individual training of pupils (Srivastava, 1954; Foster and Ander-
son, 1978, p. 62; Mukherjee et al., 2012). Medicinal practices on
the Indian subcontinent began to intermingle with the Arab sys-
tem of medicine (Unani Tibb) from the twelfth century onward
and toward the end of the eighteenth century the British began
to introduce the Western system of medicine (Srivastava, 1954).
The ﬁrst European medical school in India, the Calcutta Medical
College, opened in 1835 (Anonymous,1879). This historical devel-
opment led to the current situation that, while the Sanskrit classics
altogether describe some 700 medicinal plant species, depending
on the source, more than 10,000 plant species are associated with
Ayurvedic medicine (Padma, 2005).
Thanks to global commercialization and intercultural knowl-
edge and information exchange, patients increasingly have the
choice between different medicinal systems for their health care
needs with access to physicians specialized within different medi-
cal systems (e.g., Miles, 1998; Khan, 2006; Stranieri and Vaughan,
2010). Based on the historical and economic development in a
country or region a nation’s traditional system(s) of medicine
is often complemented with biomedicine. Conversely, in other
regions, alongside biomedicine different traditional systems of
medicine and alternatives (complementary medicine) are estab-
lished. If and how alternative therapies should be included and
covered by national health services and what is a fair price for
individual therapies, medicine and health care in general is the
matter of continuous debates (Figure 1).
However, Khan (2006) argues that although medical pluralism
is already a historic reality in many societies there is a need to
bring the discussion beyond the pluralist and liberal arguments
FIGURE 1 | A fair price for medicine – does it exist?
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including factors such as “domination and hegemony” widening
the historical, social and political context of the discussion. With
respect to India, Khan (2006) speciﬁes, that while Western cul-
ture and medicine exerted authority over indigenous science and
medicine during the colonial phase it were the national leader-
ships and governments, which consolidated this development.
On the other hand did the demand for indigenous alternatives,
according to Khan (2006), although effective, not get enough
response from the national authorities. Likewise, local health
care and medicine is subjected to global commercialism, which
progressively inﬂuences individual therapeutic choices and pref-
erences (cf. Miles, 1998). But while patients may choose between
different medicinal systems, therapeutic settings, where special-
ists from different medicinal systems collaborate, are rare. One
recently highlighted example stems from a modern community
hospital in Thailand, where Thai Traditional Medicine is inte-
grated alongside biomedicine into the modern healthcare service
(Chotchoungchatchai et al., 2012). The identiﬁed key factors for
the successful integration are knowledge transmission of Royal
Thai Traditional Medicine and locally practiced herbal medicine
to the hospital practitioners and a healthcare team consisting
of members with different backgrounds, together with a well
organized supply of herbal medicine (Chotchoungchatchai et al.,
2012). Integrating medical systems is not only a challenge for hos-
pital facilities but also in health informatics (Health Information
Systems), which is currently closely linked to the dimensions of
Western biomedicine (Stranieri and Vaughan, 2010). Since the
trend toward co-existence of different medicinal systems is bound
to augment it is appropriate to design health informatics appli-
cations compliant with the characteristics of different medicinal
systems. The visualization of arguments pro and contra for choos-
ing a certain medicinal system in a particular health condition is
put forward by Stranieri andVaughan (2010) as an example of how
the coalescing of medicinal systems into health informatics may
support patients’ informed decisions making. In this respect Witt
(2013) argues that there is a lack of clinical studies focusing on
comparative effectiveness of traditional herbal medicine and food
products.
Traditional medicines will only be taken seriously and accepted
by primary health care systems when experimental and clinical
data establish an evidence base (Cordell, 2011; Verpoorte, 2012).
High standard studies conﬁrming the safety and the effectiveness
of traditional medicines are, therefore, required (Cordell, 2011;
Verpoorte, 2012). Since co-medication of medicinal plants and
biomedicine is frequently observed, practitioners and clinicians
are encouraged to watch out for adverse as well as beneﬁcial inter-
actions (Giovannini et al., 2011; Nagata et al., 2011; Odonne et al.,
2011). Clinical studies instead of focusing exclusively on efﬁcacy
could focus also on effectiveness by including a more heteroge-
neous sample of participants and adopting research settings that
reﬂect usual heath care situations as far as possible (Witt, 2013).
According to Verpoorte (2012) and others (see Weidenhammer
et al., 2011 andXuet al., 2013), the changing global economic scene
and changing paradigm in drug development might present an
advantage in the attempt to ofﬁcially register traditionalmedicines
with governmental agencies. However, as pronounced by Etkin
(2006, p. 212), “aggressive marketing of both pharmaceuticals
and supplements blurs the line between scientiﬁc observation and
product advertisement.”
CONCLUSION
The use of indigenous drugs, herbal medicine and traditional
materia medica can only be understood through a combination
of historical, ecological, economic, cognitive, and pharmacolog-
ical approaches, while anecdotal references are lost in space and
time. Ongoing globalization driven by neo-liberalism increases
medical plurality through intercultural knowledge and informa-
tion exchange. Although there is a trend toward the development
of global pharmacopoeias, local pharmacopoeias, despite being
inﬂuenced by global economy, and politics will continue to keep
their role and identity. While knowledge transmission along trade
and value chains tend to secure hegemonic and ﬁnancial interests
over local economies and pharmacopoeias, the local availability of
biomedicine and access to research data on traditional and herbal
medicine may lead to a syncretic development with reconciling
effects. Not only herbal products but also food supplements and
nutraceuticals have considerably raised their market share in the
last few years. Since sound scientiﬁc data for many commercial-
ized health products is still lacking, this calls for a much more
rigorous multidisciplinary science-driven approach to local and
traditional medicines, which also empowers the local keepers of
this knowledge and their users.
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